Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Role of DNA Damage Response in Suppressing Malignant Progression of Chronic Myeloid Leukemia and Polycythemia Vera: Impact of Different Oncogenes
Jan Stetka, Ján Gurský, Julie Liñan Velasquez, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 903-903
Open Access | Times Cited: 17

Showing 17 citing articles:

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4820-4820
Open Access | Times Cited: 119
Hydrogen sulfide of air induces macrophage extracellular traps to aggravate inflammatory injury via the regulation of miR-15b-5p on MAPK and insulin signals in trachea of chickens
Nuan Song, Wei Wang, Yue Wang, et al.
The Science of The Total Environment (2021) Vol. 771, pp. 145407-145407
Closed Access | Times Cited: 45
Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies
Ryan J. Stubbins, Sophia C. Korotev, Lucy A. Godley
Current Hematologic Malignancy Reports (2022) Vol. 17, Iss. 4, pp. 94-104
Closed Access | Times Cited: 24
Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
Lasse Kjær
Cancers (2020) Vol. 12, Iss. 8, pp. 2100-2100
Open Access | Times Cited: 23
Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
Andrew Kuykendall, Nathan P. Horvat, Garima Pandey, et al.
Cancers (2020) Vol. 12, Iss. 8, pp. 2278-2278
Open Access | Times Cited: 18
The active ingredients and mechanisms of Longchai Jiangxue Formula in treating PV, based on UPLC/Q-TOF-MS/MS, systematic pharmacology, and molecular biology validation
Jing Ming, Weiyi Liu, Hongwei Wu, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 140, pp. 111767-111767
Open Access | Times Cited: 17
DNA Damage Response−Related Proteins Are Prognostic for Outcome in Both Adult and Pediatric Acute Myelogenous Leukemia Patients: Samples from Adults and from Children Enrolled in a Children’s Oncology Group Study
Stefan Hübner, Eduardo Sabino de Camargo Magalhães, Fieke W. Hoff, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5898-5898
Open Access | Times Cited: 4
The importance of personalized medicine in chronic myeloid leukemia management: a narrative review
Erfan Zaker, Negar Nouri, Sepehr Sorkhizadeh, et al.
Egyptian Journal of Medical Human Genetics (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 4
The potential of circHIPK3 as a biomarker in chronic myeloid leukemia
Eduardo Wandame Gomez, Laura Berti De Paula, Rafael Diogo Weimer, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Chromosomal Instability in Chronic Myeloid Leukemia: Mechanistic Insights and Effects
Jayastu Senapati, Koji Sasaki
Cancers (2022) Vol. 14, Iss. 10, pp. 2533-2533
Open Access | Times Cited: 7
Exploiting the potential of the ubiquitin-proteasome system in overcoming tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Xudong Li, Wei Li, Yanli Zhang, et al.
Genes & Diseases (2023) Vol. 11, Iss. 5, pp. 101150-101150
Open Access | Times Cited: 3
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients
Federica Malighetti, Giulia Arosio, Chiara Manfroni, et al.
HemaSphere (2023) Vol. 7, Iss. 3, pp. e852-e852
Open Access | Times Cited: 2
Molecular Analysis of Genes CEBPA, NPM1, IDH1, and RUNX1 Polymorphisms as Biomarker Potential in Leukemia Patients
Kashif Bashir, Sadia Abdul Ghafar, Abd Ur Rehman, et al.
Molecular Carcinogenesis (2024)
Open Access
DNA polymerase kappa stabilized by PTBP2 interacts with MRE11 and promotes genomic instability in leukemia cells
Shristi Lama, Bibhudev Barik, Sajitha IS, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Mechanism of Procyanidin B2 in the Treatment of Chronic Myeloid Leukemia Based on Integrating Network Pharmacology and Molecular Docking
Hongxing Li, Yuan-Xue Jing, Yi-Hong Chai, et al.
Anti-Cancer Agents in Medicinal Chemistry (2023) Vol. 23, Iss. 16, pp. 1838-1847
Closed Access | Times Cited: 1
Investigating the Effects of a Synthetic Cannabinoid on the Pathogenesis of Leukemia and Leukemic Stem Cells: A New Therapeutic Approach
Hilal Salcın, Bakiye Göker Bağca, İlayda Alçıtepe, et al.
Cannabis and Cannabinoid Research (2022) Vol. 9, Iss. 1, pp. 212-222
Closed Access | Times Cited: 2
From bench to bedside: bridging the gaps in best practices for real-world chronic myeloid leukemia care
Giovanni Manfredi Assanto, Emilia Scalzulli, Ida Carmosino, et al.
Expert Review of Hematology (2022) Vol. 15, Iss. 11, pp. 963-971
Closed Access | Times Cited: 1
Page 1

Scroll to top